Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

PCI Announces Expansion of Packaging Capacity

Published: Friday, March 14, 2014
Last Updated: Friday, March 14, 2014
Bookmark and Share
PCI’s packaging site adds packaging space to accommodate business growth.

Packaging Coordinators, Inc. (PCI) has announced the completion of the planned expansion of its packaging facilities in Rockford, IL.

The Rockford site is one of three locations in the United States, and the facilities expansion in Rockford was designed to accommodate continued business development in its contract packaging services.

PCI converted underutilized space to further support its expanding packaging operations, adding 20,000 square feet for secondary and tertiary packaging. The additional production capacity will enable continued growth in operations such as cartoning, overwrapping, heat seal carding and compliance prompting packaging, as well as supporting packaging for biotech delivery forms such as secondary packaging for injectable vials, syringes, devices, and transdermal products. The packaging operations support both commercial operations as well as large-scale clinical studies.

In addition to packaging of commercial medicines, PCI provides clinical packaging services for investigational medicines at the Rockford location supported by on-site Storage and Distribution Services, facilitating global logistics for clinical studies.

In December 2013 PCI has announced the groundbreaking of a new 93,000 square foot Storage and Distribution site for investigational medicines, currently slated to be in operation in August of this year.

The clinical services expansion complements investments in PCI’s UK operations, most recently construction of a Storage and Distribution facility near Cardiff, Wales.

“The facilities expansion we have undertaken in Rockford is the latest in a series of investments we have made to enable continued growth and at the same time continue to provide our customers the extraordinary service they have come to expect from PCI,” states Bill Mitchell, President and Chief Executive Officer at PCI. “We are committed to providing an unparalleled customer experience with our clinical and commercial services, and those services require world class facilities. We are very excited about what these investments bring to our expanding business and our ability to support our clients.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,900+ scientific posters on ePosters
  • More than 4,200+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

PCI Announces Opening of North American Clinical Facility
PCI opens North American storage and distribution facility for investigational medicinal products.
Thursday, October 16, 2014
PCI Announces Acquisition of Biotec
Acquisition expands clinical trial and cold chain services.
Friday, September 26, 2014
Scientific News
Therapy Halts Progression of Lou Gehrig’s Disease
Researchers at Oregon State University announced today that they have essentially stopped the progression of amyotrophic lateral sclerosis (ALS), or Lou Gehrig’s disease, for nearly two years in one type of mouse model used to study the disease – allowing the mice to approach their normal lifespan.
New Mechanism of Antitumor Action Identified
A team of UAB researchers and collaborators from the Catalan biotech company Ability Pharmaceuticals (UAB Research Park), have described a new mechanism of anti-tumour action, identified during the study and development of the new drug ABTL0812.
Experimental Combination Surprises with Anti-HIV Effectiveness
A compound developed to protect the nervous system from HIV surprised researchers by augmenting the effectiveness of an investigational antiretroviral drug beyond anything expected.
UTSW Researchers Identifies How Drugs Alter Pancreatic Cancer Cells
The findings were published in Cell Reports.
Researchers Identify Process that Causes Chronic Neonatal Lung Disease
Study determines how the NLRP3 inflammasome activates the protein Interleukin 1 beta.
Dengue Vaccine Enters Phase 3 Trial
Investigational vaccine to prevent ‘breakbone fever’ developed at NIH.
Trying to Conceive Soon After a Pregnancy Loss May Increase Chances of Live Birth
NIH study finds no reason for delaying pregnancy attempts after a loss without complications.
BRCA1 Deficiency Increases the Sensitivity of Ovarian Cancer Cells to Auranofin
An anti-rheumatic drug could improve the prognosis for ovarian cancer patients exhibiting a deficiency of the DNA repair protein BRCA1, a study suggests.
Shingles Vaccine Helps Protect Older Patients with End-stage Renal Disease
Kaiser Permanente study advances knowledge about safety and effectiveness of vaccine commonly given to older adults.
AMRI Acquires Whitehouse Laboratories
Strategically extends AMRI's analytical offerings in rapidly expanding area of outsourcing services.
Scroll Up
Scroll Down
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!